--- title: "LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy" type: "News" locale: "en" url: "https://longbridge.com/en/news/284855142.md" description: "LTR Pharma has announced positive interim Phase II clinical data for its SPONTAN intranasal PDE5 therapy, showing a median time to maximum plasma concentration of 10 minutes for the 5 mg dose. The company is pursuing a dual US strategy for erectile dysfunction treatments, targeting FDA 505(b)(2) pathway for SPONTAN and earlier market entry for ROXUS. With $24.1 million in cash and no debt, LTR Pharma is well-positioned to fund operations and reach key milestones, although regulatory execution risks remain." datetime: "2026-05-01T00:59:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284855142.md) - [en](https://longbridge.com/en/news/284855142.md) - [zh-HK](https://longbridge.com/zh-HK/news/284855142.md) --- # LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy LTR Pharma has announced positive interim Phase II clinical data for its SPONTAN intranasal PDE5 therapy alongside an investor presentation detailing its US strategy and funding. Interim Phase II pharmacokinetic (PK) data for **SPONTAN** intranasal vardenafil showed a median time to maximum plasma concentration (Tmax) of **10 minutes** for the **5 mg** dose. This is significantly faster than oral vardenafil, which had a median Tmax of **60 minutes**. The data, gathered from **27 subjects** including a geriatric cohort of **14 subjects**, indicated no serious adverse events or Grade 3/4 treatment-emergent adverse events. Importantly, repeat dosing for **5 days** showed no evidence of drug accumulation, with an accumulation ratio of **1.0±0.9**. These interim PK results reportedly meet key **FDA** Pre-IND requirements and are expected to inform **LTR Pharma's** planned **FDA 505(b)(2)** regulatory pathway, with final statistical results anticipated in **Q3 CY2026**. **Dual US Strategy Detailed** **LTR Pharma** is pursuing a dual US strategy for its erectile dysfunction treatments, advancing **SPONTAN** via the **FDA 505(b)(2)** pathway, while targeting earlier US market entry for **ROXUS** through **503A personalised medicine** discussions. The company has completed extractables studies, with leachables and human factors studies currently underway to support the complex **FDA** combination product requirements for its intranasal drug-device program. Strategic partnerships with **Aptar Pharma** for co-development and manufacturing, and **Mayne Pharma** for commercial manufacturing, underpin this progress. In Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) program has provided early validation, with more than **1,000** prescriptions recorded. This real-world usage and expanding prescriber adoption offer valuable insights and support ahead of potential U.S. commercialisation. **Funding Position and Milestones** **LTR Pharma** reported a strong financial position, with **$24.1 million** in cash and zero debt. The company states this is sufficient to fund operations and reach near-term clinical and regulatory milestones. The current cash balance is intended to support crucial activities, including the completion of Phase II data readout, human factors, and toxicology studies. Key upcoming milestones for **2026** include the completion of human factors and leachables studies in **H1 2026**, with the full Phase II dataset and final results expected in **Q3 CY2026**. This will be followed by animal toxicology completion and Phase III planning. **Prior Progress and Risks** Previous reports from **March 2026** indicated the completion of recruitment for the **SPONTAN** Phase II study, with initial data expected in **Q2 2026**. The company’s **1H FY26** report showed widening losses, but its cash position remained robust, providing a runway for its programs. While the interim data is positive, regulatory execution risk remains for the **FDA** combination product requirements and acceptance of the development plan. Additionally, early US market presence via **503A** discussions is progressing but not yet confirmed as executed. Final Phase II results will provide further clarity on the drug's profile and support regulatory submissions. With sufficient funding to reach upcoming milestones, the company is positioning itself for potential US market entry, though regulatory hurdles and execution remain key considerations. ### Related Stocks - [LTRN.US](https://longbridge.com/en/quote/LTRN.US.md) - [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ATR.US](https://longbridge.com/en/quote/ATR.US.md) - [MYX.AU](https://longbridge.com/en/quote/MYX.AU.md) ## Related News & Research - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md) - [BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches](https://longbridge.com/en/news/286199057.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)